keyword
MENU ▼
Read by QxMD icon Read
search

Myeloma mortality

keyword
https://www.readbyqxmd.com/read/29787442/epidemiology-of-late-health-effects-in-ukrainian-chornobyl-cleanup-workers
#1
Dimitry Bazyka, Anatoly Prysyazhnyuk, Natalya Gudzenko, Iryna Dyagil, David Belyi, Vadim Chumak, Volodymyr Buzunov
This article summarizes the results of 30 y of follow-up of cancer and noncancer effects in Ukrainian cleanup workers after the Chornobyl accident. The number of power plant employees and first responders with acute radiation syndrome under follow-up by the National Research Center for Radiation Medicine decreased from 179 in 1986-1991 to 105 in 2011-2015. Cancers and leukemia (19) and cardiovascular diseases (21) were the main causes of deaths among acute radiation syndrome survivors (54) during the postaccident period...
July 2018: Health Physics
https://www.readbyqxmd.com/read/29781040/autologous-stem-cell-transplantation-in-first-remission-is-associated-with-better-progression-free-survival-in-multiple-myeloma
#2
Mukul Aggarwal, Narendra Agrawal, Neha Yadav, Priyanka Verma, Rayaz Ahmed, Pallavi Mehta, Jyotsna Kapoor, Dinesh Bhurani
Autologous stem cell transplant (ASCT) is standard consolidation therapy in management of multiple myeloma (MM) patients. We reviewed records of all consecutive MM patients who underwent ASCT with high-dose melphalan at our center from year 2002 to 2016. A total of 141 ASCT were conducted (90 males and 51 females) with median age of 55 years (23-68 years). Median time from diagnosis to transplant was 7 months (3-79), with majority of patients underwent transplant in first remission, while 17 (12%) patients received transplant beyond first remission...
May 21, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29751116/pharmacokinetics-of-high-dose-propylene-glycol-free-melphalan-in-multiple-myeloma-patients-undergoing-autologous-hematopoietic-cell-transplantation
#3
Binod Dhakal, Anita D'Souza, Arjun Lakshman, Mehdi Hamadani, Saurabh Chhabra, Robert Thompson, Nirav Shah, Marcelo Pasquini, Paramweswaran Hari
High dose melphalan followed by autologous stem cell transplant (ASCT) is standard of care for eligible patients with multiple myeloma (MM). EVOMELAR (propylene glycol-free melphalan HCl, PG-Free Mel) was approved by the FDA as conditioning therapy for ASCT in MM in two daily 100 mg/m2 doses for a total dose of 200 mg/m2 . In this phase II, open-label study; PG-Free Mel (EvomelaR ) conditioning was given at single dose of 200 mg/m2 on day -2 pre-ASCT in order to establish pharmacokinetic (PK) parameters and safety...
May 8, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29744908/dose-response-relationships-between-internally-deposited-uranium-and-select-health-outcomes-in-gaseous-diffusion-plant-workers-1948-2011
#4
James H Yiin, Jeri L Anderson, Stephen J Bertke, David J Tollerud
OBJECTIVE: To examine dose-response relationships between internal uranium exposures and select outcomes among a cohort of uranium enrichment workers. METHODS: Cox regression was conducted to examine associations between selected health outcomes and cumulative internal uranium with consideration for external ionizing radiation, work-related medical X-rays and contaminant radionuclides technetium (99 Tc) and plutonium (239 Pu) as potential confounders. RESULTS: Elevated and monotonically increasing mortality risks were observed for kidney cancer, chronic renal diseases, and multiple myeloma, and the association with internal uranium absorbed organ dose was statistically significant for multiple myeloma...
May 9, 2018: American Journal of Industrial Medicine
https://www.readbyqxmd.com/read/29730782/myeloma-light-chain-cast-nephropathy-a-review
#5
REVIEW
Insara Jaffer Sathick, Maria Eleni Drosou, Nelson Leung
Multiple Myeloma is a plasma cell proliferative disorder that commonly involves the kidney. Renal impairment is a serious complication during the course of the disease that is associated with increased morbidity and mortality. Light chain cast nephropathy is the predominant pattern of renal injury in Multiple Myeloma. This review article focuses on the pathophysiology and diagnostic approach of myeloma cast nephropathy. The management of precipitating factors as well as anti-plasma cell treatment modalities in the context of renal impairment are also discussed...
May 5, 2018: Journal of Nephrology
https://www.readbyqxmd.com/read/29721251/bone-targeted-agents-in-multiple-myeloma
#6
Hiroko Nishida
Osteolytic bone disease, characterized by bone pain, increased risk of pathologic fractures, tumor-induced hypercalcemia known as skeletal-related events (SREs), is a frequent complication of patients with multiple myeloma (MM) and persists even in the absence of active disease, resulting in a major cause of morbidity and mortality. The interaction between myeloma cells and their surrounding cells in the bone marrow (BM) microenvironment promotes both myeloma cell growth and bone destruction and forms the vicious cycle of MM bone disease...
March 2, 2018: Hematology Reports
https://www.readbyqxmd.com/read/29713245/allogeneic-stem-cell-transplantation-for-multiple-myeloma-a-systematic-review-and-meta-analysis-from-2007-to-2017
#7
Xuejiao Yin, Liang Tang, Fengjuan Fan, Qinyue Jiang, Chunyan Sun, Yu Hu
Background: Despite recent advances, multiple myeloma (MM) remains incurable. However, the appearance of allogeneic stem cell transplantation (allo-SCT) through graft-versus-myeloma effect provides a potential way to cure MM to some degree. This systematic review aimed to evaluate the outcome of patients receiving allo-SCT and identified a series of prognostic factors that may affect the outcome of allo-SCT. Patients/methods: We systematically searched PubMed, Embase, and the Cochrane Library from 2007...
2018: Cancer Cell International
https://www.readbyqxmd.com/read/29692879/temporal-trends-in-survival-and-healthcare-costs-in-patients-with-multiple-myeloma-in-the-united-states
#8
Eric M Maiese, Kristin A Evans, Bong-Chul Chu, Debra E Irwin
Background: In recent years, the development of new therapies for multiple myeloma has improved the survival of patients, but newer treatments may also affect healthcare costs. To date, no real-world study has examined the concurrent changes in survival and total healthcare costs over time in patients with multiple myeloma. Objective: To examine the temporal changes in survival and healthcare costs among patients with multiple myeloma in the United States. Method: This retrospective claims-based cohort study is based on death files in the Truven Health MarketScan Research Commercial and Medicare Supplemental databases...
February 2018: American Health & Drug Benefits
https://www.readbyqxmd.com/read/29692592/revisiting-renal-amyloidosis-with-clinicopathological-characteristics-grading-and-scoring-a-single-institutional-experience
#9
Abhiram Kalle, Archana Gudipati, Sree Bhushan Raju, Karthik Kalidindi, Swarnalatha Guditi, Gangadhar Taduri, Megha S Uppin
INTRODUCTION: Kidney involvement is a major cause of mortality in systemic amyloidosis. Glomerulus is the most common site of deposition in renal amyloidosis, and nephrotic syndrome is the most common presentation. Distinction between AA and AL is done using immunofluorescence (IF) and immunohistochemistry (IHC). Renal biopsy helps in diagnosis and also predicting the clinical course by applying scoring and grading to the biopsy findings. MATERIALS AND METHODS: The study includes all cases of biopsy-proven renal amyloidosis from January 2008 to May 2017...
April 2018: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/29684563/long-term-results-of-prophylactic-donor-lymphocyte-infusions-for-patients-with-multiple-myeloma-after-allogeneic-stem-cell-transplantation
#10
Maximilian Gröger, Nico Gagelmann, Christine Wolschke, Ute-Marie von Pein, Evgeny Klyuchnikov, Max Christopeit, Axel Zander, Francis Ayuk, Nicolaus Kröger
The major reason for treatment failure after allografting in multiple myeloma (MM) is relapse. Donor lymphocyte infusions (DLIs) are considered a valuable post-transplant strategy mainly for relapsed patients but using them to prevent relapse in MM has been reported rarely. In the present study, we examined the efficacy of prophylactic DLIs after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in myeloma patients with a long-term follow-up of more than 5 years. A total of 61 patients with MM who did not relapse or develop disease progression after allo-HSCT were treated with prophylactic DLI in an escalating fashion (overall 132 DLI procedures) to deepen remission status and prevent relapse...
April 21, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29674497/plasma-cell-proliferative-index-predicts-outcome-in-immunoglobulin-light-chain-amyloidosis-treated-with-stem-cell-transplantation
#11
M Hasib Sidiqi, Mohammed Aljama, Dragan Jevremovic, William G Morice, Michael Timm, Francis K Buadi, Rahma Warsame, Martha Q Lacy, Angela Dispenzieri, David Dingli, Wilson I Gonsalves, Shaji Kumar, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, William J Hogan, Morie Gertz
The plasma cell proliferative index provides an insight into plasma cell biology in plasma cell disorders and is an important prognostic marker in myeloma and smoldering myeloma. We analyzed the prognostic impact of the plasma cell proliferative index in 513 patients with systemic AL Amyloidosis undergoing stem cell transplantation at the Mayo Clinic between January 2003 and 31 August 2016. Two cohorts were identified; Low or Elevated plasma cell proliferative index. Patients with an Elevated plasma cell proliferative index had more cardiac involvement (56% vs 44%; p=0...
April 19, 2018: Haematologica
https://www.readbyqxmd.com/read/29616871/dcep-as-a-bridge-to-ongoing-therapies-for-advanced-relapsed-and-or-refractory-multiple-myeloma
#12
Hiu Lam Agnes Yuen, Michael Sze Yuan Low, Pasquale Fedele, Anna Kalff, Patricia Walker, Krystal Bergin, John Coutsouvelis, George Grigoriadis, Andrew Spencer
There is limited data describing dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in relapsed refractory multiple myeloma (RRMM). We reviewed 65 patients with RRMM receiving DCEP between 2005 and 2017 in two Melbourne Hospitals. Patients had received a mean of three prior treatment lines (range, 1-11). The mean number of cycles of DCEP was two (range, 1-4). Overall response rate (ORR) was 55% whilst 19% achieved MR and SD. Median overall survival (OS) was 9.6 months. Those bridged to autologous stem cell transplant (ASCT) had significantly improved OS compared to those who were not (median 32...
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29606981/pleural-effusion-in-11-14-translocation-q1-multiple-myeloma-in-the-setting-of-proteasome-inhibitor-presents-therapeutic-complexity
#13
Malik Ghannam, Maria Bryan, Erik Kuross, Brent Berry
Background: Primary malignant pleural effusion has been reported in about 134 cases of multiple myeloma (MM). Associated pleural effusions in cases of MM portend a poor prognosis and identifying them is highly relevant. Reported is the case of a man diagnosed with MM who developed primary myelomatous pleural effusion in the setting of multiple relapses and subsequent mortality within 2 months of the pleural effusion diagnosis. Presentation: A 61-year-old African American man was diagnosed with MM in 2011...
2018: Memo
https://www.readbyqxmd.com/read/29589466/a-systematic-review-of-epidemiologic-studies-of-styrene-and-cancer
#14
James J Collins, Elizabeth Delzell
Previous epidemiology reviews of exposure to styrene and the risk of cancer considered studies published through 13 November 2013. Since then, additional relevant research has been published. No review has included meta-analyses. The current systematic review considered research published through June 2017; included meta-analyses of the relationship between any exposure to styrene and cancers identified as being of concern, including non-Hodgkin lymphoma (NHL), leukemia and cancers of the esophagus, pancreas, lung and kidney; and evaluated several other forms of cancer...
March 28, 2018: Critical Reviews in Toxicology
https://www.readbyqxmd.com/read/29587222/occupational-extremely-low-frequency-magnetic-fields-elf-mf-exposure-and-hematolymphopoietic-cancers-swiss-national-cohort-analysis-and-updated-meta-analysis
#15
Anke Huss, Adrian Spoerri, Matthias Egger, Hans Kromhout, Roel Vermeulen
PURPOSE: Previous studies have examined risks of leukaemia and selected lymphoid malignancies in workers exposed to extremely low frequency magnetic fields (ELF-MF). Most studies evaluated hematolymphopoietic malignancies as a combined category, but some analyses suggested that effects may be contained to some specific leukaemia or lymphoma subtypes, with inconsistent results. METHODS: We examined exposure to ELF-MF and mortality 1990-2008 from different types of hematolymphopoietic cancers in the Swiss National Cohort, using a job exposure matrix for occupations recorded at censuses 1990 and 2000...
March 24, 2018: Environmental Research
https://www.readbyqxmd.com/read/29584537/early-mortality-in-elderly-patients-undergoing-treatment-for-multiple-myeloma-in-real-world-practice
#16
Jun Xia, Lingling Wang, Xin Zhou, Jing Wang, Huan Wang, Hongfeng Guo
Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29578426/dysfunction-of-various-organ-systems-induced-by-sepsis-with-underlying-severe-myelomic-diseases-and-prostate-cancer-case-report
#17
L Ratiani, N Intskirveli, L Goliadze, T Chkhikvadze, L Koptonashvili, E Khuchua
A 65-year-old male patient, unconscious, was admitted into the clinic by the Ambulance. From the patient's medical history it was revealed that several hours before the admission in the clinic the following symptoms were present: shortness of breath, fever, hypotonia, consciousness inhibition, because of which emergency brigade was called and was brought by the Emergency Brigade. The history is loaded by chronic pathologies: myeloma disease, prostate cancer, ciliary arrhythmia, heart failure; received several courses of polichemotherapy, last ten days has been treated for pneumonia with antibiotics of ceftriaxone group in outpatient setting...
February 2018: Georgian Medical News
https://www.readbyqxmd.com/read/29573332/epidemiology-of-multiple-myeloma-in-17-latin-american-countries-an-update
#18
Maria Paula Curado, Max M Oliveira, Diego R M Silva, Dyego L B Souza
The objective of this study was to describe incidence, mortality rates, and trends for multiple myeloma (MM) in Latin America (LA), contributing to better knowledge on the epidemiology of MM in this continent. Incidence data were extracted from the International Agency for Research on Cancer (IARC), for the period 1990-2007. Mortality data were obtained for 17 countries from the World Health Organization, for the period 1995-2013. Annual average percentage change (AAPC) and 95% confidence interval (95% CI) were calculated for incidence and mortality...
March 24, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29564621/addition-of-doxycycline-to-ciprofloxacin-for-infection-prophylaxis-during-autologous-stem-cell-transplants-for-multiple-myeloma
#19
J M Sivik, J Davidson, C M Hale, J J Drabick, G Talamo
BACKGROUND: The most commonly used antibacterial prophylaxis during autologous stem cell transplants (ASCT) for multiple myeloma (MM) involves a fluoroquinolone, such as ciprofloxacin or levofloxacin. We assessed the impact of adding doxycycline to ciprofloxacin as routine antibacterial prophylaxis in these patients. METHODS: We retrospectively reviewed electronic medical records and our ASCT database to analyze rates and types of bacterial infections in MM patients who underwent ASCT in our institution...
March 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29555314/the-role-of-allogeneic-transplantation-for-multiple-myeloma-in-the-era-of-novel-agents-a-study-from-the-japanese-society-of-myeloma
#20
Koji Kawamura, Nobuhiro Tsukada, Yoshinobu Kanda, Takashi Ikeda, Akiyo Yoshida, Yasunori Ueda, Tadao Ishida, Kenshi Suzuki, Hirokazu Murakami
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered a potentially curative therapy for patients with multiple myeloma, the role of allo-HSCT remains unclear in the novel agent era. We conducted a retrospective study of 65 patients with multiple myeloma who underwent allo-HSCT at 19 institutions from 2009 to 2016. Patients received a median of 3 (range, 1 to 7) lines of prior therapy, including at least 1 novel agent, except for autologous HSCT. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 18...
March 16, 2018: Biology of Blood and Marrow Transplantation
keyword
keyword
58221
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"